The Atrial Fibrillation Problem
Only in Europe, 6 million people in Europe suffer from Atrial Fibrillation (AF), the most common cardiac arrhythmia. By 2050, 2% of the world population will be affected by this condition. The highly effective treatment is ablation. However, a precise diagnosis comes first. This is where the challenge lies. Only with a detailed diagnosis, ablation treatments can be really effective.
The Solution: ACORYS
Corify develops ACORYS: a Non-invasive Electrocardiographic Imaging device that resolves the main shortcomings of existing solutions to identify the optimal treatment in each patient with Atrial Fibrillation.